These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22994083)

  • 1. [Specific features of hypolipidemic therapy in patients with abdominal ischemic disease].
    Oĭnotkinova OSh
    Ter Arkh; 2012; 84(8):18-21. PubMed ID: 22994083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention.
    Ishii H; Nishio M; Takahashi H; Aoyama T; Tanaka M; Toriyama T; Tamaki T; Yoshikawa D; Hayashi M; Amano T; Matsubara T; Murohara T
    Clin Ther; 2010 Dec; 32(14):2337-47. PubMed ID: 21353104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging.
    Yonemura A; Momiyama Y; Fayad ZA; Ayaori M; Ohmori R; Higashi K; Kihara T; Sawada S; Iwamoto N; Ogura M; Taniguchi H; Kusuhara M; Nagata M; Nakamura H; Tamai S; Ohsuzu F
    J Am Coll Cardiol; 2005 Mar; 45(5):733-42. PubMed ID: 15734619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effect of co-administration of atorvastatin and endothelin-1 receptor antagonist on the progression of atherosclerosis in rabbit.
    Sun Y; Liu J; Yang B; Sai X; Li T; Wang D; Zhou R
    APMIS; 2014 Jun; 122(6):556-64. PubMed ID: 24164644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
    Markovic-Plese S; Jewells V; Speer D
    Neurology; 2009 Jun; 72(22):1965; author reply 1965-6. PubMed ID: 19487658
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
    JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results of randomized study: intensive lipid lowering treatment stops coronary atherosclerosis].
    MMW Fortschr Med; 2004 Mar; 146(13):64-5. PubMed ID: 15219142
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
    Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    J Am Coll Cardiol; 2015 Aug; 66(5):495-507. PubMed ID: 26227186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The last round about statins: there is the fact that 80 mg simvastatin daily results in high risk of myopathy].
    Olsson AG
    Lakartidningen; 2009 Oct 21-27; 106(43):2783-4; author reply 2784. PubMed ID: 19960911
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
    Mascitelli L; Pezzetta F; Goldstein MR; Chaturvedi S
    Neurology; 2009 Jul; 73(3):249; author reply 249-50. PubMed ID: 19620618
    [No Abstract]   [Full Text] [Related]  

  • 11. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
    Barrios V; Amabile N; Paganelli F; Chen JW; Allen C; Johnson-Levonas AO; Massaad R; Vandormael K
    Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting vascular risk in patients with metabolic syndrome but without diabetes.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Didangelos TP; Peletidou A; Kleta D; Karagiannis A; Kakafika AI; Tziomalos K; Elisaf M
    Metabolism; 2005 Aug; 54(8):1065-74. PubMed ID: 16092057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Statins: for the time being, do not as a rule prescribe the maximum dose].
    Smulders YM
    Ned Tijdschr Geneeskd; 2005 Aug; 149(34):1876-8. PubMed ID: 16136739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia.
    Wägner AM; Jorba O; Bonet R; Ordóñez-Llanos J; Pérez A
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3212-7. PubMed ID: 12843167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of the efficacy of atorvastatin in treating patients with dyslipidaemia to target LDL-cholesterol goals: the atorvastatin matrix study.
    McVey D; Patel H; Eminton Z; Maton S
    Int J Clin Pract; 1999; 53(7):509-13. PubMed ID: 10692735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
    Georgescu EF; Georgescu M
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):39-46. PubMed ID: 17410287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.
    Foster T; Budoff MJ; Saab S; Ahmadi N; Gordon C; Guerci AD
    Am J Gastroenterol; 2011 Jan; 106(1):71-7. PubMed ID: 20842109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised study to compare the efficacy and safety of isapgol plus atorvastatin versus atorvastatin alone in subjects with hypercholesterolaemia.
    Jayaram S; Prasad HB; Sovani VB; Langade DG; Mane PR
    J Indian Med Assoc; 2007 Mar; 105(3):142-5, 150. PubMed ID: 17824470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial.
    Kawahara T; Nishikawa M; Kawahara C; Inazu T; Sakai K; Suzuki G
    Circulation; 2013 Jun; 127(23):2327-35. PubMed ID: 23658438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.
    Bays H; Gaudet D; Weiss R; Ruiz JL; Watts GF; Gouni-Berthold I; Robinson J; Zhao J; Hanotin C; Donahue S
    J Clin Endocrinol Metab; 2015 Aug; 100(8):3140-8. PubMed ID: 26030325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.